NICE Approves Breast Cancer Drug for Wider Group of NHS Patients
Trastuzumab deruxtecan will now be available to patients with HER2-low and ultralow tumors, a decision campaigners say could benefit thousands of women in England.

England's health spending watchdog NICE has approved the drug trastuzumab deruxtecan for a broader group of breast cancer patients, including those whose tumors show very low levels of the HER2 protein.
The decision extends National Health Service access to patients with HER2-low and HER2-ultralow metastatic breast cancer, groups for whom the targeted antibody-drug conjugate had previously been out of reach on cost-effectiveness grounds.
Clinical trials showed the treatment slowed disease progression compared with standard chemotherapy. NICE had earlier rejected the drug for some of these patients, citing uncertainty over its value at the manufacturer's asking price.
Charities called the approval a milestone, estimating thousands of patients a year could benefit. The manufacturer agreed to a confidential discount, and NHS England said eligible patients should be able to begin treatment within weeks.


